Pharming Group

Pharming Group PP&E per Employee

The PP&E per Employee of Pharming Group (PHARM.AS) as of Nov 19, 2026 is 184,646.23 USD. In the previous year, PP&E per Employee was 156,438.68 USD — a change of 18.03% (higher).

PP&E per Employee

184,646.23USD

YoY

18.03%

Last updated:

PP&E per Employee of Pharming Group is 2022 184,646.23 USD. PP&E per Employee of Pharming Group was 2021 156,438.68 USD. It decreases by 18.03% higher compared to the previous year.

The Pharming Group PP&E per Employee history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

PP&E per Employee
Date
PP&E per Employee
Jan 1, 2015
26,702.83 USD
Jan 1, 2016
28,504.72 USD
Jan 1, 2017
38,839.62 USD
Jan 1, 2018
39,632.08 USD
Jan 1, 2019
76,863.21 USD
Jan 1, 2020
102,136.79 USD
Jan 1, 2021
156,438.68 USD
Jan 1, 2022
184,646.23 USD
The Pharming Group PP&E per Employee history
YEARPP&E per EmployeeYoY
184,646.23USD+18.03%
156,438.68USD+53.17%
102,136.79USD+32.88%
76,863.21USD+93.94%
39,632.08USD+2.04%
38,839.62USD+36.26%
28,504.72USD+6.75%
26,702.83USD+1.13%
26,405.66USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Pharming Group Stock analysis

What does Pharming Group do? Pharming Group NV was founded in 1988 and is headquartered in the Netherlands. The company specializes in the development and marketing of medical products for the treatment of rare diseases. Its business model is based on the discovery and development of recombinant proteins. These proteins are produced using genetic engineering techniques and serve as the foundation for the development of therapeutic products in various areas. The main focus of Pharming Group NV is the manufacturing and marketing of biopharmaceuticals. The company has a wide range of products used in the treatment of rare diseases, including C1-esterase inhibitor preparations used for acute attacks in hereditary angioedema. Another important product of Pharming Group NV is recombinant human lysozyme. It is used in the treatment of cystic fibrosis and has shown promising results as a therapeutic approach. Pharming Group NV also collaborates closely with various research and development organizations to develop new products and expand knowledge in the medical industry. The company has experienced impressive growth in recent years. In 2019, Pharming Group NV achieved a revenue of 149 million euros. A significant portion of this revenue was generated through the sale of C1-esterase inhibitor preparations. Pharming Group NV has also made a name for itself in the international market. The company has branches in the USA and Europe and works closely with international regulatory authorities to ensure smooth approval and marketing of its products. Overall, Pharming Group NV has a promising future as it continues to invest in research, development, and expansion of its product portfolio. By focusing on the development of products for the treatment of rare diseases, Pharming Group NV positions itself as a leading company in the medical industry and contributes to improving the lives of people worldwide. Pharming Group is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Pharming Group stock

PP&E per Employee of Pharming Group is 184,646.23 USD in 2022.

PP&E per Employee of Pharming Group changed from 156,438.68 USD to 184,646.23 USD, representing a 18.03% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of PP&E per Employee Pharming Group since 2006 – with annual values, charts, and detailed analysis.

PP&E per employee measures the physical capital intensity per worker. Higher values indicate more capital-intensive operations.

PP&E per Employee's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track PP&E per Employee's Pharming Group historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Workforce — Pharming Group

All Key Metrics — Pharming Group